Prostaglandin E1 suppresses tumor necrosis factor-α and interleukin-10 production by lipopolysaccharides-stimulated mononuclear cells

European Journal of Pharmacology

Volumn 344, Issue 1, 1998, Pages 95-98

  Ishikawa, Osamu ^a   Kubota, Yae ^a   Miyachi, Yoshiki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Interleukin 10; Lipopolysaccharide; Mononuclear cells; Prostaglandin E1; TNF (tumor necrosis factor )

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; MESSENGER RNA;

ARTICLE; CONCENTRATION RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; MONONUCLEAR CELL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; BIOSYNTHESIS; DRUG EFFECT; GENETICS; IN VITRO STUDY; MALE; METABOLISM;

ADULT; ALPROSTADIL; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032567818     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01575-6     Document Type: Article

References (20)

1. Abecassis M. Treatment of fulminant hepatic failure with a continuous infusion of prostin VR (PGE1). Hepatology. 7:1987;1104. abstract.
2. Carlson L.A., Eriksson F. Femoral artery infusion of prostaglandin E1 in severe peripheral vascular diseases. Lancet. i:1973;155-156.
3. Carlson L.A., Olsson A.G. Intravenous prostaglandin E1 in severe vascular diseases. Lancet. ii:1976;810.
4. DiGiovine F.S., Nuki G., Duff G.W. Tumor necrosis factor in synovial exsudates. Ann. Rheum. Dis. 47:1988;768-772.
5. Groves R.W., Allen M.H., Ross E.L., Barker J.N.W.N., MacDonald D.M. Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br. J. Dermatol. 132:1995;345-352.
6. Haynes D.R., Whitehouse M.W., Vernon-Roberts B. The prostaglandin E1, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology. 76:1992;251-257.
7. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: Association with pulmonary fibrosis. J. Rheumatol. 24:1997;663-665.
8. Leirisalo-Repo M., Paimela L., Jäättelä M., Koskimies S., Repo H. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Scand. J. Rheumatol. 24:1995;366-371.
9. Maury C.P.J., Salo E., Pelkonen P. Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J. Lab. Clin. Med. 113:1989;651-654.
10. Muto Y., Mouri-Aria K.T., Meager A., Alexander G.J., Eddleston A.L., Williams R. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet. ii:1988;72-74.
11. Piguet P.E., Grau G.E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J. Exp. Med. 166:1987;1280-1289.
12. Piguet P.E., Grau G.E., Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am. J. Pathol. 136:1990;103-110.
13. Piguet P.E., Grau G.E., Hauser C., Vassalli P. Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173:1991;673-679.
14. Schrror, K., 1991. Cellular sites of action of prostaglandins in the cardiovascular system. In: Dieham, C., Sinzinger, H., Rogatti, W. (Eds.), Prostaglandin E1 - New Aspects on Pharmacology, Metabolism and Clinical Efficacy. Springer-Verlag, Berlin, pp. 1-5.
15. Shimizu Y., Mizutani H., Inachi S., Tsuchibashi T., Shimizu M. Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis. J. Dermatol. 21:1994;755-759.
16. Solis-Herruzo J.A., Brenners D.A., Chojkier M. Tumor necrosis factor α inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J. Biol. Chem. 263:1988;5841-5845.
17. Tracey K.J., Wei H., Manogue K.R., Fong Y., Hesse D.G., Nguyen H.T., Kuo G.C., Beutler B., Cotran R.S., Cerami A. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1988;1211-1227.
18. Yamanaka K., Mizutani H., Hashimoto K., Nishii M., Shimizu M. Scleroderma renal crisis complicated by hemolytic uremic syndrome in a case of elderly onset systemic sclerosis. J. Dermatol. 24:1997;184-188.
19. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:1995;775-779.
20. Vilcek, J., Tsujimoto, M., Palombella, V.J., Kohase, M., Junming, L.E., 1987. Tumor necrosis factor: Receptor binding and mitogenic action in fibroblasts. J. Cell. Physiol. Suppl. 5, 57-61.